Brought to you by 
Artios licenses DNA damage repair program from Cancer Research Technology
20 Sep 2017
Executive Summary
Cancer Research UK's Cancer Research Technology granted new oncology biotech Artios Pharma Ltd. rights to two targets in the field of DNA damage response (DDR).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Artios licenses DNA damage repair program from Cancer Research Technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice